Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1987 Oct;46(10):741–745. doi: 10.1136/ard.46.10.741

Indications of vascular endothelial cell dysfunction in systemic lupus erythematosus.

M A Byron 1, M J Allington 1, H M Chapel 1, A G Mowat 1, S A Cederholm-Williams 1
PMCID: PMC1003380  PMID: 3500677

Abstract

Fibrinolytic and other factors have been measured in 73 patients with systemic lupus erythematosus or related conditions to determine whether clinical thrombosis, a common feature of these disorders, is associated with defective fibrinolysis. Twenty five of 72 (35%) patients, compared with two of 22 (9%) controls, showed a low level of plasminogen activator activity in response to venous occlusion, suggesting decreased fibrinolytic potential. In addition, mean plasma levels of von Willebrand factor antigen and fibronectin were markedly raised in the patients (mean (SD) 384.5 (277)% and 727 (436) mg/l respectively) compared with healthy controls (100 (50)% and 306 (65) mg/l). These data suggest a degree of endothelial cell dysfunction. No clear correlation was found between a history of thrombosis and any plasma factor measured, except for prolongation of clotting tests suggestive of the 'lupus anticoagulant'.

Full text

PDF
741

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angles-Cano E., Sultan Y., Clauvel J. P. Predisposing factors to thrombosis in systemic lupus erythematosus: possible relation to endothelial cell damage. J Lab Clin Med. 1979 Aug;94(2):312–323. [PubMed] [Google Scholar]
  2. Boey M. L., Colaco C. B., Gharavi A. E., Elkon K. B., Loizou S., Hughes G. R. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J (Clin Res Ed) 1983 Oct 8;287(6398):1021–1023. doi: 10.1136/bmj.287.6398.1021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Byron M. A. The clotting defect in SLE. Clin Rheum Dis. 1982 Apr;8(1):137–151. [PubMed] [Google Scholar]
  4. Carreras L. O., Defreyn G., Machin S. J., Vermylen J., Deman R., Spitz B., Van Assche A. Arterial thrombosis, intrauterine death and "lupus" antiocoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet. 1981 Jan 31;1(8214):244–246. doi: 10.1016/s0140-6736(81)92087-0. [DOI] [PubMed] [Google Scholar]
  5. Cederholm-Williams S. A. Automated enzyme assay of antithrombin. Ann Clin Biochem. 1980 Jul;17(4):183–184. doi: 10.1177/000456328001700404. [DOI] [PubMed] [Google Scholar]
  6. Clark R. A., Quinn J. H., Winn H. J., Lanigan J. M., Dellepella P., Colvin R. B. Fibronectin is produced by blood vessels in response to injury. J Exp Med. 1982 Aug 1;156(2):646–651. doi: 10.1084/jem.156.2.646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Collen D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost. 1980 Jun 18;43(2):77–89. [PubMed] [Google Scholar]
  8. Dornan T. L., Rhymes I. L., Cederholm-Williams S. A., Rizza C. R., Pepys M. B., Bron A. J., Turner R. C. Plasma haemostatic factors and diabetic retinopathy. Eur J Clin Invest. 1983 Jun;13(3):231–235. doi: 10.1111/j.1365-2362.1983.tb00093.x. [DOI] [PubMed] [Google Scholar]
  9. Glas-Greenwalt P., Kant K. S., Allen C., Pollak V. E. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus. J Lab Clin Med. 1984 Dec;104(6):962–976. [PubMed] [Google Scholar]
  10. Green D., Hougie C., Kazmier F. J., Lechner K., Mannucci P. M., Rizza C. R., Sultan Y. Report of the Working Party on Acquired Inhibitors of Coagulation: studies of the "lupus" anticoagulant. Thromb Haemost. 1983 Apr 28;49(2):144–146. [PubMed] [Google Scholar]
  11. Haitas B., Barnes A. J., Cederholm-Williams S. A., Moore J., Shogry M. E., Turner R. C. Abnormal endothelial release of fibrinolytic activity and fibronectin in diabetic microangiopathy. Diabetologia. 1984 Nov;27(5):493–496. doi: 10.1007/BF00290382. [DOI] [PubMed] [Google Scholar]
  12. Jaffe E. A., Mosher D. F. Synthesis of fibronectin by cultured human endothelial cells. J Exp Med. 1978 Jun 1;147(6):1779–1791. doi: 10.1084/jem.147.6.1779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kant K. S., Pollak V. E., Weiss M. A., Glueck H. I., Miller A. N., Hess E. V. Glomerular thrombosis in systemic lupus erythematosus: prevalence and significance. Medicine (Baltimore) 1981 Mar;60(2):71–86. doi: 10.1097/00005792-198103000-00001. [DOI] [PubMed] [Google Scholar]
  14. Lahiri A., Robinson C. W., Tovey J., Caruana M. P., Kohli R. S., Harlow B. J., Raftery E. B. Intravenous nicardipine in patients with chronic heart failure: a nuclear stethoscope study. Postgrad Med J. 1984;60 (Suppl 4):35–38. [PubMed] [Google Scholar]
  15. Laurell C. B. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem. 1966 Apr;15(1):45–52. doi: 10.1016/0003-2697(66)90246-6. [DOI] [PubMed] [Google Scholar]
  16. Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  17. Nilsson I. M., Ljungnér H., Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J (Clin Res Ed) 1985 May 18;290(6480):1453–1456. doi: 10.1136/bmj.290.6480.1453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. O'Connor N. T., Cederholm-Williams S., Copper S., Cotter L. Hypercoagulability and coronary artery disease. Br Heart J. 1984 Dec;52(6):614–616. doi: 10.1136/hrt.52.6.614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Robertson B. R., Pandolfi M., Nilsson I. M. "Fibrinolytic capacity" in healthy volunteers at different ages as studied by standardized venous occlusion of arms and legs. Acta Med Scand. 1972 Mar;191(3):199–202. [PubMed] [Google Scholar]
  20. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  21. Thiagarajan P., Shapiro S. S., De Marco L. Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest. 1980 Sep;66(3):397–405. doi: 10.1172/JCI109869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Wautier J. L., Paton R. C., Wautier M. P., Pintigny D., Abadie E., Passa P., Caen J. P. Increased adhesion of erythrocytes to endothelial cells in diabetes mellitus and its relation to vascular complications. N Engl J Med. 1981 Jul 30;305(5):237–242. doi: 10.1056/NEJM198107303050501. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES